Please wait a minute...
  2006, Vol. 25 Issue (5): 0-0    
  儿科用药专栏 本期目录 | 过刊浏览 | 高级检索 |
黄芪注射液对特发性肾病综合征患儿血清IL-10的影响
林飞进1,高岩2,陈述枚3,赵继宗4,黄金城1,崔敏娴1
1.浙江中医学院附属第二医院儿科,杭州310007;2.广州市儿童医院肾内科,510120;3.中山大学附属第一医院儿科,广州510080;4.中山大学附属第一医院外科实验室,广州510080
Effect of Astragalus for Injection on Serum Level of Interleukin10 in Children with Idiopathic Nephrotic Syndrome
LIN Feijin;GAO Yan;CHEN Shumei;ZHAO Jizong;HUANG Jincheng;CUI Minxian
1.Department of Pediatrics, the Second Hospital Affiliated with the Zhejiang College of Traditional Chinese Medicine, Hangzhou 310007, China;2. Department of Nephrology, Guangzhou Children’s Hospital, Guangzhou 510120, China;3. Department of Pediatrics, the First Hospital Affiliated with the Yatsen University, Guangzhou 510080, China;4. Laboratory of Surgery, the First Hospital Affitiated with the Yatsen University, Guangzhou 510080 China
全文: PDF(1254 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的观察黄芪注射液对特发性肾病综合征(INS)患儿血清白细胞介素10(IL-10)水平的影响。方法63例未用过糖皮质激素治疗或诊断为INS,但使用糖皮质激素治疗已完全缓解并停用激素>3个月又复发的INS患儿,随机分为治疗组A33例和治疗组B30例。治疗组A给予泼尼松口服治疗,1.5~2.0 mg·kg-1·d-1,qd;另加用黄芪注射液0.5 mL·kg-1·d-1;同时给予利尿、抗感染等对症处理;治疗组B除不给予黄芪注射液外,其他治疗同治疗组A。两组均在INS初发期和治疗1个月后采用双抗体夹心ELISA方法检测血清IL-10水平。另设25例正常儿童为对照组。结果发病初期,治疗组A和治疗组B血清IL-10水平均较正常对照组高(均P<0.01)。治疗组B经泼尼松治疗后血清IL10水平[(9.36±3.43) pg·mL-1]较治疗前明显降低(P<0.01),且与正常对照组比较,差异无显著性(P>0.05);治疗组A治疗后血清IL10水平[(12.10±4.14) pg·mL-1]与本组治疗前比较,差异无显著性;仍较正常对照组和治疗组B治疗后高,且均差异有显著性(均P<0.05)。结论黄芪注射液能防止INS患儿血清IL-10水平降低,能对抗激素对IL-10产生的抑制作用,这可能是黄芪注射液降低INS患儿尿蛋白含量的作用机制之一.
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
关键词 黄芪注射液肾病综合征特发性白细胞介素10(IL-10)    
AbstractObjectiveTo detect the effect of astragalus for injection together with glucocorticoid on serum levels of IL-10 in children with idiopathic nephrotic syndrome(INS), to analyse their role in INS and the mechanism of astragalus' treatment for INS. MethodsSixtythree children with idiopathic nephrotic syndrome were divided into astragalus group including thirtythree cases and nonastragalus group including thirty cases. In astragalus group, patients were given prednisone 1.5-2.0 mg·kg-1·d-1,P.O., qd, astragalus for injection 0.5 mL·kg-1·d-1, and other symptomatic treatments. In nonastragalus group except astragalus for injection, other treatments were the same as the first group. The serum IL10 levels in all patients between initial stage and one month after therapy were detected. Other 25 healthy children were collected in control group. Serum IL10 levels were detected by a double antibody "sandwich" ELISA. ResultsIn initial stage, there was no significant difference in serum IL10 level between nonastragalus group and astragalus group (14.05±5.57) pg·mL-1 vs (13.39±6.14) pg·mL-1(t=0.61,P>0.05), and both were higher than control group [(14.05±5.57) pg·mL-1 vs (9.48±4.01) pg·mL-1, t=3.36, P<0.01, and (13.39±6.14) pg·mL-1 vs (9.48±4.01) pg·mL-1, t=2.77, P<0.01]. Serum IL-10 levels in nonastragalus group after prednisone therapy were significantly lower than those before prednisone therapy (9.36±3.43) pg·mL-1 vs (14.05±5.57) pg·mL-1, t=3.55, P<0.01, and no significant difference was observed as compared with control group. Compared with those before treatment, Serum IL-10 levels in astragalus group were not significant different in initial stage and one month after prednisone together with astragalus therapy(t=0.95,P>0.05. Serum IL10 levels of astragalus group in one month after prednisone together with astragalus therapy were still significantly higher than those in control group(12.10±4.14) pg·mL-1 vs (9.48±4.01) pg·mL-1, t=2.25,P<0.05 and nonastragalus group in one month after prednisone therapy(12.10±4.14) pg·mL-1 vs (9.36±3.43)pg·mL-1, t=2.40,P<0.05).ConclusionAstragalus for injection can prevent the lowering of serum IL-10 levels in children with idiopathic nephrotic syndrome and counteract the inhibitory effect of hormone on the production of IL-10. This may be one of the mechanism of astragalus for injection to lower the urine protein content in children with INS.
收稿日期: 1900-01-01      出版日期: 2006-05-01
通讯作者: 林飞进   
引用本文:   
林飞进;高岩;陈述枚;赵继宗;黄金城;崔敏娴. 黄芪注射液对特发性肾病综合征患儿血清IL-10的影响[J]. , 2006, 25(5): 0-0.
LIN Feijin;GAO Yan;CHEN Shumei;ZHAO Jizong;HUANG Jincheng;CUI Minxian. Effect of Astragalus for Injection on Serum Level of Interleukin10 in Children with Idiopathic Nephrotic Syndrome . , 2006, 25(5): 0-0.
链接本文:  
http://www.yydbzz.com//CN/      或      http://www.yydbzz.com//CN/Y2006/V25/I5/0
[1] 陈本川编译. 治疗慢性特发性便秘新药—— 普卡那肽(plecanatide)[J]. 医药导报, 2017, 36(6): 716-721.
[2] 李桂水,杨敏京,边连朵,张永辉. 抗幽门螺杆菌治疗在特发性血小板减少性紫癜治疗中的临床意义[J]. 医药导报, 2016, 35(增刊): 15-16.
[3] 胡秀芬,高峰. 全身型幼年特发性关节炎发病机制及治疗进展[J]. 医药导报, 2016, 35(12): 1287-1290.
[4] 张蕾. 干扰素γ-1b对特发性肺间质纤维化疗效分析[J]. 医药导报, 2015, 34(4): 480-482.
[5] 丁艳;尹薇;刘凡;曾小燕;谢彤. 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗幼年特发性关节炎32例[J]. , 2015, 34(2): 193-197.
[6] 胡丽玲;王燕燕;彭艳;. 人血清蛋白治疗肾病综合征水肿1例[J]. , 2014, 33(3): 395-397.
[7] 曾明;程樱. 黄芪注射液联合针刺穴位对慢性肾小球肾炎模型大鼠的治疗作用[J]. , 2014, 33(1): 24-27.
[8] 刘亭;辛华雯;吴笑春;余爱荣;郭珩 . 1例老年肾病综合征并发急性脑梗死患者的药学监护[J]. , 2013, 32(10): 1375-1377.
[9] . 升血小板胶囊联合泼尼松治疗成人慢性特发性血小板减少性紫癜[J]. , 2012, 31(4): 440-441.
[10] 李飞;杨定平 . 诺新康注射液辅助治疗原发性肾病综合征40例[J]. , 2011, 30(9): 1162-1165.
[11] 王鸿祥;陈斌 . 特发性男性不育症的药物治疗进展*[J]. , 2011, 30(12): 1625-1628.
[12] 关欣;郑红光. 他克莫司治疗难治性肾病综合征1例[J]. , 2011, 30(02): 219-220.
[13] 张晶;何胜虎. 卡托普利与黄芪注射液对人脐静脉内皮细胞凋亡的影响[J]. , 2010, 29(2): 157-162.
[14] 扈瑞娥;刘淑萍. 103例肾病综合征住院患者用药分析[J]. , 2008, 27(11): 1418-1419.
[15] 魏琴;施钰琳. 杏丁注射液辅助治疗原发性肾病综合征78例[J]. , 2007, 26(8): 897-0898.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   

通信地址:武汉市蔡甸区中法生态城同济医院专家社区C栋平层《医药导报》编辑部,邮政编码:430199
鄂ICP备07004419号
版权所有:《医药导报》编辑部
网址:www.yydb.cn;www.yydbzz.com
电话:027-69378382,69378383 电子邮箱: yydbzz@163.com
技术支持:北京玛格泰克科技发展有限公司 鄂ICP备09001709号-11